BMS
BMS, Pharmacyclics and Janssen collaborate on cancer
October 14, 2014Research and Development, Sales and Marketing BMS, Janssen, Pharmacyclics, imbruvica, opdivo
Bristol-Myers Squibb, Pharmacyclics and Janssen are to collaborate on clinical trials combining BMS’s cancer drug Opdivo (nivolumab) with Janssen and …
BMS pulls hep C combo treatment in US
October 7, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Combo, HCV, asunaprevir, daclatasvir, hep C, sovaldi
Bristol-Myers Squibb will not attempt to bring its new combination hepatitis C treatment to the US market given the current …
BMS therapeutic cancer vaccine given swift FDA appraisal
September 29, 2014Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, Vaccine, bristol myers-squibb, keytruda, melanoma, opdivo
Bristol-Myers Squibb has been granted a speedy review for its new cancer immunotherapy drug Opdivo by the FDA for patients …
BMS sues Merck over new melanoma drug
September 8, 2014Research and Development, Sales and Marketing BMS, FDA, Merck, PD-1 inhibitors, Yervoy, keytruda
Things are getting ugly between Bristol-Myers Squibb and Merck as the former company began legal proceedings against the latter over …
Bristol-Myers Squibb: following the string of pearls
September 8, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, BMS, GSK, Johanna Mercier, Pfizer, UCB, Yervoy, acquisitions
Bristol-Myers Squibb (BMS) is something of an enigma in the pharma industry. Whilst many of its big pharma peers are …
Pfizer/BMS blood thinner gains new licence
August 22, 2014Sales and Marketing BMS, DVT, Eliquis, Pfizer, Pradaxa, Xarelto, blood, warfarin
Pfizer and Bristol-Myers Squibb have been handed a much-needed lift after its new blood thinner Eliquis gained a licence extension …
AZ and Mitsubishi partner on diabetic nephropathy
August 20, 2014Research and Development, Sales and Marketing AstraZeneca, BMS, Mitsubishi, cvmd, diabetes, nephropathy
AstraZeneca and Japanese firm Mitsubishi Tanabe Pharma Corporation (MTPC) have signed a new three-year research deal in the area of …
NICE ‘yes’ for cancer drugs
July 23, 2014Sales and Marketing Astellas, BMS, Cancer, NICE, Xtandi, Yervoy
Two big-name oncology brands, Bristol-Myers Squibb’s Yervoy and Astellas Pharma’s Xtandi, have been given the nod by drug costs watchdog …
BMS to make Opdivo submission
July 11, 2014Sales and Marketing BMS, Cancer, EMA, FDA, ono, opdivo, pd-1
Bristol-Myers Squibb is to submit cancer treatment Opdivo to the US authorities after the drug received its first approval in …
World’s first anti-PD-1 therapy approved
July 8, 2014Research and Development, Sales and Marketing BMS, Cancer, melanoma, nivolumab, ono, opdivo
Ono Pharmaceutical has been given the world’s first licence for a new type of cancer treatment on which many researchers’ …
CHMP approves six drugs including daclatasvir
June 30, 2014Sales and Marketing BMS, CHMP, HCV, Plavix, daclatasvir, daklinza, ge
A key advisory committee for the European Medicines Agency has given its approval to six new drugs at its latest …
BMS expands data transparency
June 27, 2014Medical Communications, Sales and Marketing BMS, best electronic cigarettes, csr, dcri, transparency
Bristol-Myers Squibb is to expand access to its clinical trial data – but researchers’ requests will have to be approved …
New BMS cancer treatment shines
June 25, 2014Research and Development, Sales and Marketing ASCO, BMS, Cancer, Yervoy, braf, melanoma, nivolumab
Bristol-Myers Squibb’s investigational cancer treatment nivolumab has helped patients with the deadliest form of skin cancer to live longer. The …
NICE recommends Yervoy
June 13, 2014Sales and Marketing BMS, Cancer, Dillon, NHS, NICE, Yervoy, melanoma
Bristol-Myers Squibb has received a lift from the UK’s drugs watchdog, which has recommended its vaccine Yervoy as a first-line …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
